Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Combining MAP-1:CD35 or MAP-1:CD55 fusion proteins with pattern-recognition molecules as novel targeted modulators of the complement cascade

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Influence of FGF23 and Klotho on male reproduction: Systemic vs direct effects

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Muscle-strain injury exudate favors acute tissue healing and prolonged connective tissue formation in humans

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Shiga Toxin 2a Binds to Complement Components C3b and C5 and Upregulates Their Gene Expression in Human Cell Lines

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Lectin complement pathway initiators after subarachnoid hemorrhage - an observational study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Soluble collectin-12 mediates C3-independent docking of properdin that activates the alternative pathway of complement

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Local complement activation is associated with primary graft dysfunction after lung transplantation

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Complement Activation and Thrombin Generation by MBL Bound to β2-Glycoprotein I

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

Dysregulation of the complement system is involved in the pathogenesis of several diseases, and its inhibition has been shown to be a feasible therapeutic option. Therefore, there is an interest in the development of complement modulators to treat complement activation-related inflammatory pathologies. Mannose-binding lectin (MBL)/ficolin/collectin-associated protein-1 (MAP-1) is a regulatory molecule of the lectin pathway (LP), whereas complement receptor 1 (CD35) and decay-accelerating factor (CD55) are membrane-anchored regulators with effects on the central effector molecule C3. In this study, we developed 2 novel soluble chimeric inhibitors by fusing MAP-1 to the 3 first domains of CD35 (CD351-3) or the 4 domains of CD55 (CD551-4) to modulate the complement cascade at 2 different stages. The constructs showed biologic properties similar to those of the parent molecules. In functional complement activation assays, the constructs were very efficient in inhibiting LP activation at the level of C3 and in the formation of terminal complement complex. This activity was enhanced when coincubated with recombinant LP recognition molecules MBL and ficolin-3. Recombinant MAP-1 fusion proteins, combined with recombinant LP recognition molecules to target sites of inflammation, represent a novel and effective therapeutic approach involving the initiation and the central and terminal effector functions of the complement cascade.-Pérez-Alós, L., Bayarri-Olmos, R., Skjoedt, M.-O., Garred, P. Combining MAP-1:CD35 or MAP-1:CD55 fusion proteins with pattern-recognition molecules as novel targeted modulators of the complement cascade.

OriginalsprogEngelsk
TidsskriftFASEB Journal
Vol/bind33
Udgave nummer11
Sider (fra-til)12723-12734
ISSN0892-6638
DOI
StatusUdgivet - nov. 2019

ID: 58007557